New drug BAL0891 enters human trials for Tough-to-Treat cancers
NCT ID NCT05768932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for side effects. About 260 adults will take part across multiple groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, South Korea
Contact
-
Baylor University Medical Center
RECRUITINGDallas, Texas, 75246, United States
Contact
-
Korean University Anam Hospital
RECRUITINGSeoul, South Korea
Contact
-
Mary Crowley Cancer Research
COMPLETEDDallas, Texas, 75230, United States
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact
-
Montefiore Medical Center - Montefiore Hospital
RECRUITINGNew York, New York, 10467, United States
Contact
-
New York Medicine-New York-Presbyterian Hospital
RECRUITINGNew York, New York, 10021, United States
Contact
-
OHSU Knight Cancer Institute
COMPLETEDPortland, Oregon, 97239, United States
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, South Korea
Contact
-
The Catholic University of Korea, Seoul St. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University of Miami Health System
RECRUITINGCoral Gables, Florida, 33146, United States
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
-
Winship Cancer Institute / Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?